Darin J. Weber Sells 16,438 Shares of ProKidney Corp. (NASDAQ:PROK) Stock

ProKidney Corp. (NASDAQ:PROK) SVP Darin J. Weber sold 16,438 shares of the firm’s stock in a transaction dated Monday, April 22nd. The stock was sold at an average price of $2.51, for a total value of $41,259.38. Following the sale, the senior vice president now directly owns 155,194 shares of the company’s stock, valued at $389,536.94. The transaction was disclosed in a document filed with the SEC, which is available through this link.

ProKidney Price Performance

NASDAQ:PROK opened at $2.71 on Thursday. The stock has a market cap of $621.51 million, a P/E ratio of -4.75 and a beta of 1.08. The company has a fifty day moving average price of $1.66 and a 200 day moving average price of $1.72. ProKidney Corp. has a one year low of $1.12 and a one year high of $13.51.

ProKidney (NASDAQ:PROK) last announced its earnings results on Thursday, March 21st. The company reported ($0.09) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.10. As a group, equities research analysts anticipate that ProKidney Corp. will post -0.65 EPS for the current year.

Institutional Investors Weigh In On ProKidney

A number of hedge funds have recently made changes to their positions in PROK. Federated Hermes Inc. increased its position in shares of ProKidney by 10,984.7% during the 4th quarter. Federated Hermes Inc. now owns 113,286 shares of the company’s stock worth $202,000 after purchasing an additional 112,264 shares in the last quarter. Jump Financial LLC bought a new stake in ProKidney during the 3rd quarter worth about $216,000. SG Americas Securities LLC grew its holdings in ProKidney by 174.2% during the 4th quarter. SG Americas Securities LLC now owns 46,829 shares of the company’s stock worth $83,000 after acquiring an additional 29,749 shares during the last quarter. Finally, Zullo Investment Group Inc. bought a new stake in ProKidney during the 1st quarter worth about $32,000. Institutional investors and hedge funds own 51.59% of the company’s stock.

Analyst Upgrades and Downgrades

PROK has been the subject of a number of recent research reports. Morgan Stanley initiated coverage on ProKidney in a research note on Thursday, March 7th. They set an “equal weight” rating and a $3.00 price target for the company. Bank of America lowered ProKidney from a “buy” rating to a “neutral” rating in a report on Tuesday, January 2nd.

ProKidney Company Profile

ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease.